BO17706
Überprüfung der Wirksamkeit und Sicherheit, wenn man Bevacizumab mit Gemcitabin und Erlotinib verabreicht, bei Patienten mit metastasiertem Pankreaskarzinom
Rekrutierung
Die Studie ist geschlossen.Studiendesign
randomisierte, doppelblinde, Placebo kontrollierte, multizentrische Phase-III-StudieSynopsis
This study will evaluate efficacy, safety and tolerability of Avastin (Bevacizumab) versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer. The anticipated time of study treatment is until confirmed evidence of disease progression, and the target sample size is 500+ individuals.Einschlusskriterien
- adult patients, ≥18 years of age
- metastatic pancreatic cancer (adenocarcinoma)
- good liver, kidney, and bone marrow function
Ausschlusskriterien
- previous systemic treatment for metastatic pancreatic cancer
- pregnant or lactating females
- fertile men, or women of childbearing potential, not using adequate contraception
- major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start
- current or recent treatment (within 30 days prior to starting study treatment) with another investigational drug, or participation in another investigational study
Studienassistentin
Frau Gudrun Gröger, Telefon: 06131 17-5443Studienleiter
Herr PD Dr. Stephan KanzlerWeitere Informationen